G

ood morning, everyone, and welcome to the middle of the week. Congratulations on making it this far and remember there are only a couple more days until the weekend arrives. So keep plugging away. We, in fact, are endeavoring to do just that as we near the end of a fruitful road trip. Once again, this means our posting will be limited, but the void will be filled by a few trusty colleagues. Meanwhile, please enjoy a few tidbits. Hope your day is a success …

The Food and Drug Administration in October issued 325 complete response letters to 325 abbreviated new drug applications and approved or tentatively approved 101 applications, Regulatory Focus observes. These are the highest numbers in a single month since the enactment of Generic Drug User Fee Amendments.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.